Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TRISHA WISE-DRAPER

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1306162367
CMS profile
1348174
Location
CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$19,550.73

20 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $16,695.39 14
Janssen Scientific Affairs, LLC $1,762.50 1
Caris MPI, Inc. $1,092.84 5

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TRISHA WISE-DRAPER

NPI 1306162367 · CMS profile ID 1348174

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1306162367?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TRISHA WISE-DRAPER, NPI 1306162367, CMS profile ID 1348174. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306162367?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). TRISHA WISE-DRAPER, NPI 1306162367, CMS profile ID 1348174. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306162367?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
TRISHA WISE-DRAPER, NPI 1306162367, CMS profile ID 1348174, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1306162367?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

20 matching records · $19,550.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 20 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–20 of 20.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Scientific Affairs, LLC $1,762.5012/18/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1174186592 CMS
Merck Sharp & Dohme LLC $1,280.0012/15/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1238035606 CMS
Merck Sharp & Dohme LLC $6,400.0009/10/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238037722 CMS
Caris MPI, Inc. $75.0009/04/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1234289700 CMS
Caris MPI, Inc. $300.0007/10/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1234289695 CMS
Caris MPI, Inc. $600.0006/05/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1234289692 CMS
Merck Sharp & Dohme LLC $155.3506/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238219958 CMS
Caris MPI, Inc. $19.2505/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234289689 CMS
Merck Sharp & Dohme LLC $30.0005/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238021482 CMS
Caris MPI, Inc. $98.5905/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234289685 CMS
Merck Sharp & Dohme LLC $7,040.0005/12/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1238036818 CMS
Merck Sharp & Dohme LLC $150.0005/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238038234 CMS
Merck Sharp & Dohme LLC $59.6005/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237996764 CMS
Merck Sharp & Dohme LLC $55.0005/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237997748 CMS
Merck Sharp & Dohme LLC $158.3305/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238001368 CMS
Merck Sharp & Dohme LLC $60.0005/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238010020 CMS
Merck Sharp & Dohme LLC $316.9205/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238029748 CMS
Merck Sharp & Dohme LLC $383.1305/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238003858 CMS
Merck Sharp & Dohme LLC $461.0705/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238028472 CMS
Merck Sharp & Dohme LLC $145.9905/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238033480 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $262.13 3
PY2020 $590.34 6
PY2021 $1,500.00 1
PY2023 $7,777.55 11
PY2024 $14,141.99 15
PY2025 $19,550.73 20

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,091,344.57 191
PY2024 Recipient $1,142.00 1
PY2024 Principal investigator $1,113,643.03 103
PY2023 Principal investigator $647,553.50 123
PY2022 Principal investigator $951,903.86 101
PY2021 Principal investigator $1,602,672.00 113
PY2020 Recipient $2,270.00 3
PY2020 Principal investigator $2,351,551.68 45
PY2019 Principal investigator $1,957,016.08 55

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

113 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $201.23 12/31/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
MEDI9447 CD73 Solid Tmr-D6070C00001 Phase 1 Clinical Trial No dispute reported 06/30/2026 826504015
Principal investigator 1 Merck Sharp & Dohme Corporation $49,349.60 12/31/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY, LLC
Phase II investigation of adjuvant combined cisplatin and radiation with pembrolizumab in resected HNSCC No dispute reported 06/30/2026 848739235
Principal investigator 1 Daiichi Sankyo Inc. $3,194.10 12/22/2021 Non-covered Recipient Entity
Uc Healthcare System
DS8201-A-J101 No dispute reported 06/30/2026 835067065
Principal investigator 1 Epizyme, Inc., $12,780.35 12/17/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832340833
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842917311
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842917357
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842917427
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842917479
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842917485
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842917491
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842917601
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842917625
Principal investigator 1 EMD Serono, Inc. $1,008.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842917671
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842917723
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842917729
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842917757
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842917809
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842917843
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842917909
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842917944
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842918037
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842918071
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842918101
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842918142
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842918189
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842918201
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842918247
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842918271
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842918293
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842918411
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842918451
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842918475
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842918527
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842918533
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842918685
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842918695
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842918729
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842918765
Principal investigator 1 EMD Serono, Inc. $628.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842918777
Principal investigator 1 EMD Serono, Inc. $259.20 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842918817
Principal investigator 1 EMD Serono, Inc. $628.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842918823
Principal investigator 1 EMD Serono, Inc. $628.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842919203
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842919333
Principal investigator 1 EMD Serono, Inc. $1,008.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842920311
Principal investigator 1 EMD Serono, Inc. $1,008.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842920329
Principal investigator 1 EMD Serono, Inc. $1,008.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842920393
Principal investigator 1 EMD Serono, Inc. $1,008.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842920475
Principal investigator 1 EMD Serono, Inc. $1,008.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842920551
Principal investigator 1 EMD Serono, Inc. $1,008.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842920585
Principal investigator 1 EMD Serono, Inc. $1,008.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842920597
Principal investigator 1 EMD Serono, Inc. $1,008.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842920725
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842920743
Principal investigator 1 EMD Serono, Inc. $1,008.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842920779
Principal investigator 1 EMD Serono, Inc. $1,008.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842920783
Principal investigator 1 EMD Serono, Inc. $1,008.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842920813
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842920861
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842920873
Principal investigator 1 EMD Serono, Inc. $1,008.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842920915
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842920933
Principal investigator 1 EMD Serono, Inc. $1,008.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842920967
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842920995
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842921001
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842921037
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842921051
Principal investigator 1 EMD Serono, Inc. $1,008.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842921073
Principal investigator 1 EMD Serono, Inc. $1,008.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842921103
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842921131
Principal investigator 1 EMD Serono, Inc. $948.00 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842921423
Principal investigator 1 GlaxoSmithKline, LLC. $109,753.92 12/14/2021 Non-covered Recipient Entity
UC HEALTH LABORATORY
0000000000000000000000000000000000000000000000000000000000000000214358 No dispute reported 06/30/2026 965538935
Principal investigator 1 GlaxoSmithKline, LLC. $5,184.70 12/10/2021 Non-covered Recipient Entity
UC HEALTH LABORATORY
0000000000000000000000000000000000000000000000000000000000000000214358 No dispute reported 06/30/2026 965538867
Principal investigator 1 EMD Serono, Inc. $415.20 12/09/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842920207
Principal investigator 1 GlaxoSmithKline, LLC. $82,673.07 12/07/2021 Non-covered Recipient Entity
UC HEALTH PHARMACY
AN OPEN-LABEL, PHASE II STUDY EVALUATING THE EFFICACY OF NIRAPARIB AND No dispute reported 06/30/2026 809515315
Principal investigator 1 Alkermes, Inc. $8,476.00 11/17/2021 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) No dispute reported 06/30/2026 797818189
Principal investigator 1 Alkermes, Inc. $1,364.45 11/17/2021 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) No dispute reported 06/30/2026 797818845
Principal investigator 1 Alkermes, Inc. $6,075.00 11/17/2021 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) No dispute reported 06/30/2026 797819299
Principal investigator 1 GlaxoSmithKline, LLC. $4,147.76 11/16/2021 Non-covered Recipient Entity
UC HEALTH LABORATORY
0000000000000000000000000000000000000000000000000000000000000000214358 No dispute reported 06/30/2026 965538929
Principal investigator 1 GlaxoSmithKline, LLC. $91,461.60 11/16/2021 Non-covered Recipient Entity
UC HEALTH LABORATORY
0000000000000000000000000000000000000000000000000000000000000000214358 No dispute reported 06/30/2026 965538933
Principal investigator 1 Eli Lilly and Company $1,331.94 10/26/2021 Covered Recipient Teaching Hospital
CHILDRENS HOSPITAL MEDICAL CENTER
A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) No dispute reported 06/30/2026 819447227
Principal investigator 1 GlaxoSmithKline, LLC. $7,258.58 10/26/2021 Non-covered Recipient Entity
UC HEALTH LABORATORY
0000000000000000000000000000000000000000000000000000000000000000214358 No dispute reported 06/30/2026 965538939
Principal investigator 1 Alkermes, Inc. $4,391.95 10/12/2021 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) No dispute reported 06/30/2026 797817597
Principal investigator 1 Alkermes, Inc. $11,709.00 10/12/2021 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) No dispute reported 06/30/2026 797819081
Principal investigator 1 GlaxoSmithKline, LLC. $3,110.82 09/21/2021 Non-covered Recipient Entity
UC HEALTH LABORATORY
0000000000000000000000000000000000000000000000000000000000000000214358 No dispute reported 06/30/2026 965538861
Principal investigator 1 GlaxoSmithKline, LLC. $164,630.88 09/21/2021 Non-covered Recipient Entity
UC HEALTH LABORATORY
0000000000000000000000000000000000000000000000000000000000000000214358 No dispute reported 06/30/2026 965539011
Principal investigator 1 Merck Sharp & Dohme Corporation $199,995.20 09/15/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
Phase II investigation of adjuvant combined cisplatin and radiation with pembrolizumab in resected HNSCC No dispute reported 06/30/2026 848739233
Principal investigator 1 GlaxoSmithKline, LLC. $164,630.88 09/08/2021 Non-covered Recipient Entity
UC HEALTH LABORATORY
0000000000000000000000000000000000000000000000000000000000000000214358 No dispute reported 06/30/2026 965538853
Principal investigator 1 GlaxoSmithKline, LLC. $7,258.58 09/08/2021 Non-covered Recipient Entity
UC HEALTH LABORATORY
0000000000000000000000000000000000000000000000000000000000000000214358 No dispute reported 06/30/2026 965538855
Principal investigator 1 EMD Serono, Inc. $1,300.00 08/26/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842909555
Principal investigator 1 EMD Serono, Inc. $1,300.00 08/26/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842910571
Principal investigator 1 EMD Serono, Inc. $53,625.00 08/26/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842911651
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,234.30 08/20/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
MEDI9447 CD73 Solid Tmr-D6070C00001 Phase 1 Clinical Trial No dispute reported 06/30/2026 826462409
Principal investigator 1 GlaxoSmithKline, LLC. $5,184.70 07/27/2021 Non-covered Recipient Entity
UC HEALTH LABORATORY
0000000000000000000000000000000000000000000000000000000000000000214358 No dispute reported 06/30/2026 965538863
Principal investigator 1 GlaxoSmithKline, LLC. $109,753.92 07/27/2021 Non-covered Recipient Entity
UC HEALTH LABORATORY
0000000000000000000000000000000000000000000000000000000000000000214358 No dispute reported 06/30/2026 965538943
Principal investigator 1 AstraZeneca Pharmaceuticals LP $330.00 07/22/2021 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-label, Phase II Study of Durvalumab (MEDI4736) in combination with Cetuximab in Previously Treated Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 826498383
Principal investigator 1 GlaxoSmithKline, LLC. $5,400.00 07/09/2021 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 809483481
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $16,260.65 07/08/2021 Non-covered Recipient Entity
University Of Cincinnati
Phase I II FIH Monotherapy Nivo Combination No dispute reported 06/30/2026 819903883
Principal investigator 1 GlaxoSmithKline, LLC. $6,221.64 06/17/2021 Non-covered Recipient Entity
UC HEALTH LABORATORY
0000000000000000000000000000000000000000000000000000000000000000214358 No dispute reported 06/30/2026 965538937
Principal investigator 1 Daiichi Sankyo Company LTD $750.00 05/10/2021 Non-covered Recipient Entity
UC Health System
DS8201-A-J101 No dispute reported 06/30/2026 831386851
Principal investigator 1 GlaxoSmithKline, LLC. $4,147.76 04/23/2021 Non-covered Recipient Entity
UC HEALTH LABORATORY
0000000000000000000000000000000000000000000000000000000000000000214358 No dispute reported 06/30/2026 965538865
Principal investigator 1 AstraZeneca UK Limited $18,373.03 04/08/2021 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Phase 1b 2 Open Label Multicentre Study Assessing the Safety Tolerability Pharmacokinetics and Preliminary Anti tumour Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and or Metastatic Squamous Cell Carcinoma of the Head and Neck No dispute reported 06/30/2026 826486221
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $42.34 03/25/2021 Non-covered Recipient Entity
University Of Cincinnati Medical Center
Phase I II FIH Monotherapy Nivo Combination No dispute reported 06/30/2026 819903895
Principal investigator 1 Alkermes, Inc. $26,037.45 03/24/2021 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) No dispute reported 06/30/2026 797817869
Principal investigator 1 Epizyme, Inc., $21,195.00 03/11/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832338903
Principal investigator 1 GlaxoSmithKline, LLC. $146,338.56 03/09/2021 Non-covered Recipient Entity
UC HEALTH LABORATORY
0000000000000000000000000000000000000000000000000000000000000000214358 No dispute reported 06/30/2026 965538947
Principal investigator 1 GlaxoSmithKline, LLC. $6,221.64 03/03/2021 Non-covered Recipient Entity
UC HEALTH LABORATORY
0000000000000000000000000000000000000000000000000000000000000000214358 No dispute reported 06/30/2026 965538857
Principal investigator 1 Eli Lilly and Company $28,914.00 03/02/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) No dispute reported 06/30/2026 819470083
Principal investigator 1 GlaxoSmithKline, LLC. $2,981.46 02/23/2021 Non-covered Recipient Entity
UC HEALTH LABORATORY
0000000000000000000000000000000000000000000000000000000000000000214358 No dispute reported 06/30/2026 965538931
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,330.00 02/16/2021 Non-covered Recipient Entity
University Of Cincinnati
Phase II 1L Metastatic H&N Single Arm Nivo Ipi Combo No dispute reported 06/30/2026 819903851
Principal investigator 1 Alkermes, Inc. $21,681.34 01/15/2021 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) No dispute reported 06/30/2026 797819923
Principal investigator 1 Daiichi Sankyo Inc. $750.00 01/13/2021 Non-covered Recipient Entity
Uc Healthcare System
DS8201-A-J101 No dispute reported 06/30/2026 835054944
Principal investigator 1 GlaxoSmithKline, LLC. $2,981.46 01/12/2021 Non-covered Recipient Entity
UC HEALTH LABORATORY
0000000000000000000000000000000000000000000000000000000000000000214358 No dispute reported 06/30/2026 965538941
Principal investigator 1 GlaxoSmithKline, LLC. $109,753.92 01/07/2021 Non-covered Recipient Entity
UC HEALTH LABORATORY
0000000000000000000000000000000000000000000000000000000000000000214358 No dispute reported 06/30/2026 965538927
Principal investigator 1 GlaxoSmithKline, LLC. $993.82 01/06/2021 Non-covered Recipient Entity
UC HEALTH LABORATORY
0000000000000000000000000000000000000000000000000000000000000000214358 No dispute reported 06/30/2026 965538859
Principal investigator 1 Merck Sharp & Dohme Corporation $4,192.00 01/04/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects with Hematologic Malignancies No dispute reported 06/30/2026 848742447